A COLUMN-SWITCHING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR A NOVEL CYTOTOXIC THIOXANTHONE DERIVATIVE (WIN-33377) IN MOUSE PLASMA WITH TOXICOKINETIC RESULTS FROM A MOUSE LD(10) STUDY

被引:4
作者
DROZD, ML
LOCKWOOD, G
MILLER, B
ROSI, D
机构
[1] Clinical Pharmacokinetics and Metabolism, Sanofi Winthrop, Inc., Sanofi Research Division, Collegeville, PA 19426-0900
来源
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS | 1995年 / 670卷 / 01期
关键词
D O I
10.1016/0378-4347(95)00155-C
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
WIN 33377 (I) is a member of a novel class of cytotoxic antitumor agents, 4-aminomethyl thioxanthone derivatives. A simple, rapid and reproducible method has been developed for the assay of I in mouse plasma using a high-performance liquid chromatographic method utilizing a column-switching technique. The method involves direct injection of buffered plasma to the extraction column for sample clean-up followed by switching onto an analytical column for analysis with UV detection at 256 nm. The method has demonstrated accuracy and precision over the range 10-2500 ng/ml using a 100-mu l plasma sample with a minimum quantifiable level at 10 ng/ml. Stability of mouse plasma samples was demonstrated after storage for 4 weeks at -15 to -20 degrees C, as was the ability of samples to be accurately quantified after a maximum of three freeze-thaw cycles. Recovery was greater than 87% for the compound and the internal standard. The assay was accurate and reproducible with measured values lying within the limits of defined acceptance criteria. The utility of the method was demonstrated by analyzing plasma samples obtained from mice dosed with I as part of a pre-clinical safety study intended to assist in the design of a pharmacokinetically guided dose escalation strategy.
引用
收藏
页码:145 / 151
页数:7
相关论文
共 5 条
[1]  
BRODFUEHRER J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P529
[2]  
COLLINS LM, 1990, NAT CANCER I, V82, P16
[3]  
GRAHAM MA, 1993, CANCER SURV, V17, P27
[4]   THE IMPACT OF PHARMACOKINETICALLY GUIDED DOSE ESCALATION STRATEGIES IN PHASE-I CLINICAL-TRIALS - CRITICAL-EVALUATION AND RECOMMENDATIONS FOR FUTURE STUDIES [J].
GRAHAM, MA ;
WORKMAN, P .
ANNALS OF ONCOLOGY, 1992, 3 (05) :339-347
[5]  
1987, EUR J CANCER CLIN ON, V7, P1083